New Prostate Cancer Test Ready for General Use

Health Discovery Corporation (HDC) announced Aug. 11 that its new gene-based molecular diagnostic test for prostate cancer has now successfully completed its phase III double-blind clinical trial. According to a Medical News Today report, the test is now ready for commercialization to be used by physicians on their patients at risk of having prostate cancer.

Comments are closed.